ACADIA Pharmaceuticals is trading at $21.60, up 6.30%; no clear company-specific catalyst was identified for the October 29 pre-market rise. - Its October 28 announcement concerned participation in the UBS Global Biopharma Conference; third-quarter results are scheduled for November 4. - Pomerantz announced an investor investigation related to earlier remlifanserin trial results on October 27; coverage does not establish it as the cause. - Major U.S. indices were lower, so broader-market strength does not explain the move.